GABAergic系统的不对称动态和GABAergic神经元在piriform发作中的悖论性反应
Yan Tao1, Yuxin Zhao1, Wenqi Zhong1
1Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science and Institutes of Brain Science, Fudan University, Shanghai, China.
Epilepsia
|December 10, 2024
概括
在皮质皮质中,改变的GABAergic神经元活动和水平有助于. 操纵这些神经元揭示了复杂的调节机制,提供了潜在的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 的研究研究.
- 在GABAergic系统动力学.
背景情况:
- 皮质状皮质 (PC) 对于细胞形成至关重要,刺激/抑制不平衡与有关.
- 在期间,GABAergic神经元的特定作用和PC中GABA系统的动态尚未完全理解.
研究的目的:
- 为了研究Gad2表达神经元和PC中的GABA水平的动态.
- 确定在活动和发育期间PC中GABAergic神经元的作用.
主要方法:
- 结合Ca2+和GABA传感器来监测Gad2神经元和GABA水平.
- 利用化学遗传学和亡来选择性地抑制或消去PC中的Gad2内部神经元.
主要成果:
- 在PC中观察到双向和不对称的GABAergic系统动态在光激发引起的发作期间.
- 化学遗传抑制PC Gad2神经元诱导了类似发作的行为,显示神经元活动和GABA水平之间的断开.
- 长期缺乏PC Gad2神经元导致自发性复发性发作,突出了它们在控制中的关键作用.
结论:
- 揭示了PC抑制电路中的复杂相互作用及其在调节中的作用.
- 证明Gad2内部神经元对于保持PC中控制至关重要.
- 这些发现表明,针对治疗的PC GABAergic神经元有潜在的治疗策略.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
328
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
328
Antiepileptic Drugs: Glutamate Antagonists
281
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
281
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
248
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
248
Seizures: Classification
300
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
300
Antiepileptic Drugs: Potassium Channel Activators
144
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
144
Postsynaptic Potential (PSP)
2.4K
Postsynaptic potential (PSP) refers to a change in the electrical potential of a neuron when neurotransmitters released by presynaptic neurons bind to postsynaptic receptors. This potential can either be excitatory, leading to depolarization and ultimately action potential generation, or inhibitory, leading to hyperpolarization and suppression of the postsynaptic neuron.
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
2.4K


